Published in Cancer Weekly, September 28th, 2004
Alpharadin, an alpha particle emitting radiopharmaceutical, is being evaluated as a potential therapy of skeletal metastases. The recently initiated phase II randomized, placebo-controlled, multicenter trial will investigate the safety and efficacy of multiple injections of Alpharadin in prostate cancer patients. The study is the first formal clinical trial with an alpha particle emitter ever being conducted in the United Kingdom.
"We are extremely pleased to have extended our phase II...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.